QANDLI DIABET: ZAMONAVIY DIAGNOSTIKA VA DAVOLASH
Ключевые слова:
Qandli diabet bugungi kunda global sog‘liqni saqlash tizimi oldidagi eng dolzarb muammolardan biri hisoblanadi. Jahon sog‘liqni saqlash tashkiloti va Xalqaro diabet federatsiyasi ma’lumotlariga ko‘ra, so‘nggi yillarda kasallikning tarqalishi keskin ortib bormoqda.Аннотация
Qandli diabet zamonaviy tibbiyotning eng dolzarb metabolik kasalliklaridan biri bo‘lib, uning tarqalishi yil sayin ortib bormoqda. Mazkur maqolada qandli diabetning zamonaviy diagnostikasi, patogenezi va davolash tamoyillari keng yoritilgan. Glyukozani uzluksiz monitoring qilish tizimlari, HbA1c diagnostikasi, sun’iy intellekt elementlari hamda individualizatsiyalashgan yondashuvlarning klinik ahamiyati tahlil qilingan. Shuningdek, GLP-1 retseptor agonistlari, SGLT2 ingibitorlari, zamonaviy insulinoterapiya va metabolik jarrohlikning samaradorligi haqida so‘nggi ilmiy ma’lumotlar keltirilgan. Diabetik nefropatiya, yurak-qon tomir asoratlari va raqamli diabetologiyaning zamonaviy imkoniyatlari ham muhokama qilingan. Maqola zamonaviy ADA va EASD tavsiyalari hamda 2023–2025-yillardagi ilmiy tadqiqotlar asosida tayyorlangan. Kalit so‘zlar: qandli diabet, insulinrezistentlik, HbA1c, CGM, GLP-1 agonistlari, SGLT2 ingibitorlari, insulinoterapiya, diabetik nefropatiya, sun’iy intellekt, raqamli diabetologiya.
Библиографические ссылки
American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl.1):S1–S350.
Buse J.B., Wexler D.J., Tsapas A. et al. 2024 Update to the Management of Hyperglycemia in Type 2 Diabetes. Diabetologia. 2024;67(3):421–449.
Cosentino F., Grant P.J., Aboyans V. et al. ESC Guidelines on Diabetes, Prediabetes and Cardiovascular Diseases. European Heart Journal. 2023;44(39):4043–4120.
Davies M.J., Aroda V.R., Collins B.S. et al. Management of Hyperglycemia in Type 2 Diabetes, 2024 Consensus Report. Diabetologia. 2024;67(1):17–56.
Del Prato S., Kahn S.E., Pavo I. Beta-cell dysfunction and therapeutic targets in type 2 diabetes. Lancet Diabetes Endocrinol. 2023;11(5):350–364.
International Diabetes Federation. IDF Diabetes Atlas. 11th edition. Brussels; 2024.
Inzucchi S.E., Bergenstal R.M., Buse J.B. Management of Hyperglycemia in Type 2 Diabetes: Contemporary Approaches. N Engl J Med. 2023;389(10):902–915.
Marx N., Federici M., Schütt K. et al. Cardiovascular outcomes with GLP-1 receptor agonists and SGLT2 inhibitors. Eur Heart J. 2024;45(4):310–329.
McGuire D.K., Shih W.J., Cosentino F. SGLT2 inhibitors in diabetic kidney disease. Circulation. 2023;148(2):121–139.
Perkovic V., Jardine M.J., Neal B. et al. Advances in diabetic nephropathy management. Kidney International. 2024;105(1):45–59.
Riddle M.C., Cefalu W.T., Evans P.H. Precision medicine in diabetes care. Diabetes Care. 2024;47(6):1100–1115.
Rubino F., Nathan D.M., Eckel R.H. Metabolic surgery in the treatment algorithm for type 2 diabetes. Ann Intern Med. 2023;176(8):1142–1150.
Shah V.N., Laffel L.M., Wadwa R.P. Continuous glucose monitoring and artificial pancreas systems. Lancet. 2024;403(10428):855–869.
Загрузки
Опубликован
Выпуск
Раздел
Как цитировать
